Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2

Dogwood Therapeutics, Inc.

2023-FY EPS reported -$0.28

Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.
R&D expenses $1.7M in FY2023 vs $8.1M in FY2022, driven by lower clinical trial costs.
Cash at Dec 31, 2023: $3.3M; expected to fund operations into Q4 2024.
FDA agreed to use fatigue as primary endpoint for IMC-2 Phase 2 in Long-COVID; initiation targeted H2 2024, pending funding.
Placebo-controlled data on valacyclovir/celecoxib for Long-COVID from Bateman Horne Center expected summer 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.